Non-Small-Cell Lung Clinical Trials in Madrid

11 recruitingMadrid, Spain

Showing 111 of 11 trials

Recruiting
Phase 2

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Squamous Non-small-cell Lung Cancer
Merck Sharp & Dohme LLC180 enrolled51 locationsNCT07221474
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 1Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 2

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Renal Cell Carcinoma (RCC)Small Cell Lung CancerNon-Small-Cell Lung
Advenchen Pharmaceuticals, LLC.80 enrolled7 locationsNCT05363280
Recruiting
Phase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled329 locationsNCT06758401
Recruiting
Phase 3

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 1Phase 2

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Colorectal, CancerUrothelial CarcinomaSquamous Non-small-cell Lung Cancer+2 more
Alentis Therapeutics AG180 enrolled28 locationsNCT07169734
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Esophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaSquamous Non-small-cell Lung Cancer+1 more
Alentis Therapeutics AG170 enrolled38 locationsNCT06747585
Recruiting
Phase 1Phase 2

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Carcinoma
AstraZeneca210 enrolled48 locationsNCT04995523
Recruiting
Phase 3

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399